Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the
TB Alliance is honored to accept a 2022 Innovating for Impact Award WASHINGTON, DC (December 7, 2022)—At the sixth annual
PRETORIA (16 November, 2022)—A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will
“The tuberculosis situation is urgent. TB is again the biggest single killer globally of any infectious disease, including COVID-19. “For
NEW YORK (Sept 19, 2022)—TB Alliance welcomes Kim Schwartz and Rasha Hibri to its Board of Directors. Their expertise will
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development
NEW YORK (June 1, 2022)—TB Alliance today announced the appointment of Pietro Turilli to the position of Senior Vice President
New Guidelines Have Potential to Transform the TB Treatment Landscape with Six-Month Standard PRETORIA (3 May 2022)—TB Alliance applauds today’s
Imagining a TB-free world amidst resurgence during COVID-19 pandemic NEW YORK (March 24, 2022)—The world continues to battle against two